MoonLake Immunotherapeutics (MLTX) Net Cash Flow (2021 - 2026)

MoonLake Immunotherapeutics' Net Cash Flow history runs 6 years deep, the most recent figure standing at -$35.5 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 138.96% year-over-year to -$35.5 million; the TTM figure through Mar 2026 stood at $26.2 million (up 114.03% YoY), while the FY2025 annual figure was $153.0 million, up 156.48% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$35.5 million, down from -$16.3 million in the prior quarter.
• The five-year high for Net Cash Flow was $451.8 million in Q2 2023, with the low at -$195.7 million in Q4 2024.
• The 5-year median for Net Cash Flow is $7.2 million (2024), against an average of $17.0 million.
• The sharpest annual moves came in 2022 and 2023: Net Cash Flow plunged 3266.85% in 2022, then soared 7962.69% in 2023.
• MoonLake Immunotherapeutics' Net Cash Flow stood at -$1.7 million in 2022, then jumped by 7962.69% to $132.9 million in 2023, then slumped by 247.18% to -$195.7 million in 2024, then surged by 91.66% to -$16.3 million in 2025, then sank by 117.93% to -$35.5 million in 2026.
• Business Quant data shows MLTX's Net Cash Flow at -$35.5 million in Q1 2026, -$16.3 million in Q4 2025, and $44.3 million in Q3 2025.